Visitor information – Everything you need to know about visiting our sites.
Alfred Health research outcomes are published in a wide range of peer reviewed journals.
Search or browse research publications by year, research area, publication type or keyword.
Publication Details
The early in-vivo effects of a single anti-emetic dose of dexamethasone on innate immune cell gene expression and activation in healthy volunteers
Bain, C.R., Draxler, D.F., Taylor, R., Wallace, S., Gouldthorpe, O., Corcoran, T.B., Myles, P.S., L. Medcalf, R., Bozaoglu, K.
(2018), Anaesthesia, 955-966
DOI: 10.1111/anae.14306
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE
(2018), Cancer Discov, 8(12), 1582-1597
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH
(2018), Leukemia, 32(2), 303-312
DOI: 10.1038/leu.2017.243
Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
Tiong IS, Reynolds J, Bradstock KF, Seymour JF, Wei AH; Australasian Leukaemia & Lymphoma Group
(2018), Blood Cancer J, 8(9), 84
DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma
Yuen HLA, Low MSY, Fedele P, Kalff A, Walker P, Bergin K, Coutsouvelis J, Grigoriadis G, Spencer A
(2018), Leuk Lymphoma, 59(12), 2842-2846
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
Tiong IS, Tan P, McManus J, Cummings N, Sadawarte S, Catalano J, Hills R, Wei A
(2018), Leuk Lymphoma, 59(2), 493-496
Autoregulation of von Willebrand factor function by a disulfide bond switch
Butera D, Passam F, Ju L, Cook KM, Woon H, Aponte-SantamarÃa C, Gardiner E, Davis AK, Murphy DA, Bronowska A, Luken BM, Baldauf C, Jackson S, Andrews R, Grâter F, Hogg PJ
(2018), Sci Adv, 4(2), eaaq1477
Mechanisms of platelet dysfunction in patients with implantable devices
Casan J, Andrews RK, Gardiner EE, Davis AK
(2018), Semin Thromb Hemost, 44(1), 43808
Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation
Yong MK, Cameron PU, Slavin MA, Cheng AC, Morrissey CO, Bergin K, Spencer A, Ritchie D, Lewin SR
(2017), Front Immunol, 8, 1506
Basic mechanisms of platelet receptor shedding
Andrews RK, Gardiner EE
(2017), Platelets, 28(4), 319-24
Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL)
Curtis DJ
(2017), Br J Haematol, 177(2), 169-70
DOI: 10.1111/bjh.14559
The cutting edge of platelets
Andrews RK, Gardiner EE
(2017), Platelets, 28(4), 317-8
Accelerating early drug development: come on down under!
Wei A
(2017), Ann Oncol, 28(7), 1655-7
Utility of CRISPR/Cas9 systems in hematology research
Lucas D, O'Leary HA, Ebert BL, Cowan CA, Tremblay CS
(2017), Exp Hematol, 54, 1-3
Up-Regulation of the Vitamin D Pathway in Acute Myeloid Leukemia
Casan JML, Ghotb S, Morgan S, Wei AH, Ting SB
(2017), Ann Hematol Oncol, 4(3), 1141
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Dàhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B?chner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Làwenberg B, Bloomfield CD
(2017), Blood, 129(4), 424-47
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, L?pez J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Bàttcher S, Ritgen M, Goede V, Mobasher M, Hallek M
(2017), Blood, 129(19), 2702-5
Challenges and opportunities in protease-activated receptor drug development
Hamilton JR, Trejo J
(2017), Annu Rev Pharmacol Toxicol, 57, 349-73
Malaria after international travel: a GeoSentinel analysis, 2003-2016
Angelo KM, Libman M, Caumes E, Hamer DH, Kain KC, Leder K, Grobusch MP, Hagmann SH, Kozarsky P, Lalloo DG, Lim PL, Patimeteeporn C, Gautret P, Odolini S, Chappuis F, Esposito DH; GeoSentinel Network
(2017), Malar J, 16, 293
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabe¡adas J, Salles G, Gaulard P, Bosly A, Coiffier B
(2017), J Clin Oncol, 35(22), 2473-81